Abstracts tagged "Disease Activity"

Abstract Number: 2031 • ACR Convergence 2020
Which Disease Activity Outcome Measure Discriminates Best in Axial Spondyloarthritis? A Systematic Literature Review and Meta-analysis
Augusta Ortolan¹, Victoria Navarro-Compán², Alexandre Sepriano³, Robert Landewé⁴, Désirée van der Heijde⁵ and Sofia Ramiro⁶, ¹Leiden University Medical Center, Padova, Italy, ²Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, ³Leiden University Medical Center, Portela Loures, Portugal, ⁴Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Several disease activity response and status criteria are used to assess treatment efficacy in RCTs in axial spondyloarthritis (axSpA). Response criteria include: the Assessment…
Abstract Number: 0198 • ACR Convergence 2020
A Prospective Cohort Study of Vehicle Control as a Measure of Driving Performance in Patients with Rheumatoid Arthritis
Kaleb Michaud¹, Jennifer Merickel¹, Yeongjin Gwon¹, Harlan Sayles¹, Haley Kampschnieder¹, Rebecca Hiebert¹, Alison Petro¹, Bryant England¹, Matthew Rizzo¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Automobile driving is an instrumental activity of daily living. Owing to symptoms and functional impairment, patients with rheumatoid arthritis (RA) rely disproportionately on driving…
Abstract Number: 0320 • ACR Convergence 2020
Assessment of Implementation of Treat to Target Concept Using Validated Composite Scores in Psoriatic Arthritis Patients
Tal Gazitt¹, Muhanad Abu Elhija¹, Amir Haddad¹, Idit Lavi¹, Muna Elias¹ and Devy Zisman¹, ¹Carmel Hospital, Haifa, Israel
Background/Purpose: To assess the implementation of the “Treat-to-Target” (T2T) concept using validated composite disease activity scores in daily management of psoriatic arthritis (PsA).Methods: A retrospective…
Abstract Number: 0725 • ACR Convergence 2020
A Data Science Evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) Questionnaire for Improving Management of JIA Patients
Humbert Quesada-Masachs¹, Michalis Faloutsos², Shomit Ghose³, Sara Marsal⁴, Consuelo Modesto⁴ and Estefania Quesada-Masachs⁵, ¹University of California Riverside, San Diego, ²University of California Riverside, Riverside, ³University of California Berkeley, San Francisco, ⁴Hospital Universitari Vall d'Hebron, Barcelona, Spain, ⁵Hospital Universitari Vall d'Hebron, San Diego
Background/Purpose: The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a questionnaire developed to comprehensively assess Juvenile Idiopathic Arthritis (JIA) patients. Despite being translated into 54…
Abstract Number: 0831 • ACR Convergence 2020
Sociodemographic, Disease, and Medication Profile of RA Patients Under 65 Years Compared with 65 Years or Older at Registry Enrollment: Real World Results from a Rheumatoid Arthritis Cohort
Mohammad Movahedi¹, Angela Cesta², Xiuying Li³ and Claire Bombardier⁴, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, Toronto, ON, Canada, ³Toronto General Hospital Research Institute, Toronto, Canada, ⁴Institute for Work and Health, Toronto, ON, Canada
Background/Purpose: Age is an important factor that can affect disease course, physical function and treat to target strategy for patients with rheumatoid arthritis (RA). We…
Abstract Number: 1018 • ACR Convergence 2020
Seasonal Variation in the Treat-to-Target Rate of Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE): A Cohort Study on Self-reported Data from Smart System of Disease Management (SSDM)
Lijun Wu¹, Zhanyun Da², Hongzhi Wang³, Jianlin Huang⁴, Bin Wu⁵, Henglian Wu⁶, Fang He⁷, Fen Wang⁸, Rong Du⁹, Linchong Su¹⁰, Qiaoqiao Yao¹¹, Rui Wu¹², Zhenbin Li¹³, Xiaohan Wang¹⁴, Yuhong Liu⁹, Chuanjing Li¹⁵, Xiaomei Lei¹⁶, Minjun Wang¹⁷, Hui Xiao¹⁷, Yuhua Jia¹⁸, Yihong Liu¹⁷, Xin Chen¹⁷, Shengsong Jia¹⁷, Bing Wu¹⁸, Yuan Liu¹⁷, Fei Xiao¹⁸ and Lingli Dong¹⁹, ¹People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China (People's Republic), ²The affiliated Hospital of Nantong University, Nantong, Jiangsu, China (People's Republic), ³The First Hospital of Jiaxing, Jiaxing, China (People's Republic), ⁴The sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China (People's Republic), ⁵Chongqing Hospital of Traditional Chinese Medicine, chongqing, Chongqing, China (People's Republic), ⁶Dongguan Donghua Hospital, Dongguan, Guangdong, China (People's Republic), ⁷Suining Central Hospital, Suining, Sichuan, China (People's Republic), ⁸The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China (People's Republic), ⁹Union Hospital Affiliated Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China (People's Republic), ¹⁰Minda Hospital of Hubei Minzu University, Enshi, Hubei, China (People's Republic), ¹¹China Resources Wuhan Iron and Steel General Hospital, Wuhan, Hubei, China (People's Republic), ¹²The First Affiliated Hospital of Nanchang University, Nanchang, China (People's Republic), ¹³Chinese people ’s liberation army joint service support force 980 hospital, shijiazhuang, Jiangxi, China (People's Republic), ¹⁴Anyang district hospital, Anyang, Henan, China (People's Republic), ¹⁵Xiaogan Central Hospital of Hubei Province, Xiaogan, Hubei, China (People's Republic), ¹⁶Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China (People's Republic), ¹⁷Shanghai Gothic Internet Technology Co., Ltd., Shanghai, Shanghai, China (People's Republic), ¹⁸Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China (People's Republic), ¹⁹Tongji Hospital Affiliated to Tongji Medical College of HUST, Wuhan, Hubei, China (People's Republic)
Background/Purpose: Treat-to-Target(T2T) is the main therapeutic strategy for patients with RA and SLE. There has been no report on comparation of seasonal variations on T2T…
Abstract Number: 1233 • ACR Convergence 2020
Use of Multi-Biomarker Disease Activity Scores to Compare Biosimilar Adalimumab-afzb (PF-06410293) with EU-Sourced Reference Adalimumab in a Phase 3, Randomized, Double-Blind Trial in Patients with Active RA
Jonathan Kay¹, Amy Bock², Noriko Iikuni³, Wuyan Zhang⁴ and Daniel Alvarez⁵, ¹University of Massachusetts Medical School, Worcester, MA, ²Pfizer, Cambridge, MA, ³Pfizer, New York, NY, ⁴Pfizer, New York, ⁵Pfizer, Collegeville, PA
Background/Purpose: Traditional efficacy endpoints of disease activity (DA) in studies of anti-rheumatic drugs can be confounded by subjective (patient-/physician-reported) assessments, comorbidities, and pre-existing joint damage.…
Abstract Number: 1460 • ACR Convergence 2020
“Can I Help You with Your RA Today?”: A Pilot Study on the User Experience with a Voice-Enabled Smartphone App to Virtually Monitor Disease Activity and Collect ePROs in Rheumatoid Arthritis
Meredith Murray¹, Stephen Penney², Adam Landman³, Josephine Elias², Emma Richard⁴, Bert Hartog⁴ and Daniel H. Solomon⁵, ¹Brigham and Women's Hospital, Medfield, MA, ²Partners Healthcare, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Janssen Research & Development, LLC, Boston, MA, ⁵Brigham & Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic disease that involves frequent patient-provider interaction and self-monitoring, both integral to successful disease management. We developed a novel…
Abstract Number: 1725 • ACR Convergence 2020
An Investigation of the Relationship Between Patient Reported Outcomes and Biomarkers in a Community Rheumatology Practice
Elston He¹, Pratyusha Yalamanchi², William Arnold³ and Erin Arnold⁴, ¹Synovium, Inc., Philadelphia, PA, ²Michigan Medicine, Ann Arbor, MI, ³Retired, Wilmette, IL, ⁴Private Practice, Orthopaedics and Rheumatology of the North Shore, Wilmette, IL
Background/Purpose: Disease presentation and progression in rheumatoid arthritis (RA) is highly heterogeneous and requires careful consideration of outcome measurements to be used for individual patients.…
Abstract Number: 1819 • ACR Convergence 2020
Altered Brain Functional Connectivity in Systemic Lupus Erythematosus
Michelle Barraclough¹, Shane McKie², Benjamin Parker¹, Alan Jackson³, Rebecca Elliott⁴ and Ian Bruce⁵, ¹Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester; NIHR Manchester Biomedical Research Centre, Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²FBMH Platform Sciences, Enabling Technologies & Infrastructure, The University of Manchester, Manchester, ³Wolfson Molecular Imaging Centre, Institute of imaging and bioinformatics, The University of Manchester, Manchester, ⁴Division of Neuroscience and Experimental Psychology, Faculty of Biology, Medicine and Health, The University of Manchester; NIHR Manchester Biomedical Research Centre, Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁵Centre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: Cognitive dysfunction (CD) is very prevalent in SLE and significantly affects quality of life. Altered functional brain mechanisms are associated with CD in SLE.…
Abstract Number: 2049 • ACR Convergence 2020
Nasal Bacteria Associated with Disease Activity and ANCA Levels in Granulomatosis with Polyangiitis
Rennie Rhee¹, Jiarui Lu¹, Kyle Bittinger², Antoine Sreih¹, Jung-Jin Lee³, Lisa Mattei³, Brendan Kelly⁴, Peter C. Grayson⁵, Hongzhe Lee⁴, Ronald Collman⁴ and Peter Merkel¹, ¹University of Pennsylvania, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Children's Hospital of Philadelphia, Philadelphia, ⁴University of Pennsylvania, Philadelphia, ⁵Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD
Background/Purpose: Nasal bacteria have been linked to disease activity in granulomatosis with polyangiitis (GPA) with most studies focused on Staphylococcus aureus. Our previous study identified…
Abstract Number: 0200 • ACR Convergence 2020
Predictors of Durable Clinical Response to Tofacitinib 11 Mg Once Daily with or Without Methotrexate in Patients with Rheumatoid Arthritis: Post Hoc Analysis of Data from a Phase 3b/4 Methotrexate Withdrawal Study
Kunihiro Yamaoka¹, Stanley B Cohen², Naonobu Sugiyama³, Harry Shi⁴, Jose L Rivas⁵, Annette Diehl⁴ and Josef Smolen⁶, ¹Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan, ²Metroplex Clinical Research Center, Dallas, TX, ³Pfizer Japan Inc, Tokyo, Japan, ⁴Pfizer Inc, Collegeville, PA, ⁵Pfizer SLU, Madrid, Spain, ⁶Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
Background/Purpose: ORAL Shift, a global Phase 3b/4 non-inferiority study, demonstrated sustained efficacy/safety of tofacitinib modified-release (MR) 11 mg QD following MTX withdrawal in patients (pts)…
Abstract Number: 0340 • ACR Convergence 2020
Neuropathic Pain Relationship with Comorbidity in Psoriatic Arthritis Patients and Its Influence on Disease Activity
Maria Elisa Acosta¹, Olga Compán², Sonia Pastor¹, Guadalupe Manzano Canabal¹, Luis Gomez-Lechon Quiros³, Cristina Hidalgo Calleja⁴, Olga Martinez Gonzalez⁵, Ana Isabel Turrión¹, Javier Del Pino-Montes¹ and Carlos Montilla Morales¹, ¹Hospital Universitario de Salamanca, Salamanca, Spain, ²Hospital Universitario de Salamanca, ´Salamanca, Spain, ³Complejo Asistencial Universitario de Salamanca, Salamanca, Spain, ⁴Hospital Universitario Salamanca, Salamanca, Spain, ⁵Hospital Universitario de Salamanca, Zamora, Spain
Background/Purpose: In psoriatic arthritis (PsA) peripheral nociceptive pain is characteristic, and is trigger by the activation of the afferent sensory fibers in the inflamed synovial…
Abstract Number: 0728 • ACR Convergence 2020
Clinical Outcomes of Juvenile Arthritis in Adulthood: A Systematic Review
Lily Siok Hoon Lim¹, Woo Jin Kim², Yushi Wang² and Kaien Gu³, ¹University of Manitoba, Children's Hospital of Manitoba, Winnipeg, MB, Canada, ²University of Manitoba Max Rady College of Medicine, Winnipeg, MB, Canada, ³University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Juvenile arthritis (JA) is the most common pediatric rheumatic disease, with potentially permanent functional impacts on patients long after initial diagnosis. Little is known…
Abstract Number: 0832 • ACR Convergence 2020
PROSARA – A Prospective, Multicenter, Noninterventional Study to Evaluate the Safety and Effectiveness of Sarilumab for the Treatment of Active Rheumatoid Arthritis in Regular Care in Germany
Eugen Feist¹, Peer-Malte Aries², Silke Zinke³, Harald Burkhardt⁴, Inka Albrecht⁵, Oliver Bley⁵, Michael Obermeier⁶, Patrizia Sternad⁷, Martin Welcker⁷, Cornelia Kühne⁸, Ann-Dörthe Holst⁹, Niklas Thomas Baerlecken¹⁰ and Hans-Peter Tony¹¹, ¹Department of Rheumatology, Helios Vogelsang-Gommern, Vogelsang-Gommern, Germany, ²Rheumatologie im Struenseehaus, Hamburg, Germany, ³Outpatient Rheumatology Center Berlin-Lichtenberg, Berlin, Germany, ⁴Department of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany, Frankfurt am Main, Germany, ⁵Sanofi Aventis Deutschland GmbH, Berlin, Germany, ⁶GKM Gesellschaft für Therapieforschung, Munich, Germany, ⁷MVZ für Rheumatologie Dr. M. Welcker, Planegg, Germany, ⁸Outpatient practice, Haldensleben, Germany, ⁹Outpatient practice, Ludwigslust, Germany, ¹⁰Rheumatology Cologne Dr. N. Baerlecken/Dr. T. Karger, Cologne, Germany, ¹¹Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany
Background/Purpose: Blockade of IL-6 signaling by sarilumab has been demonstrated to be an effective treatment approach for RA. Due to strict inclusion and exclusion criteria,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].